Literature DB >> 22704761

Towards an individualized protocol for workload increments in cardiopulmonary exercise testing in children and adolescents with cystic fibrosis.

H J Hulzebos1, M S Werkman, M van Brussel, T Takken.   

Abstract

BACKGROUND: There is no single optimal exercise testing protocol for children and adolescents with cystic fibrosis (CF) that differs widely in age and disease status. The aim of this study was to develop a CF-specific, individualized approach to determine workload increments for a cycle ergometry testing protocol.
METHODS: A total of 409 assessments consisting of maximal exercise data, anthropometric parameters, and lung function measures from 160 children and adolescents with CF were examined. 90% of the database was analyzed with backward linear regression with peak workload (W(peak)) as the dependent variable. Afterwards, we [1] used the remaining 10% of the database (model validation group) to validate the model's capacity to predict W(peak) and [2] validated the protocol's ability to provide a maximal effort within a 10±2 minute time frame in 14 adolescents with CF who were tested using this new protocol (protocol validation group).
RESULTS: No significant differences were seen in W(peak) and predicted W(peak) in the model validation group or in the protocol validation group. Eight of 14 adolescents with CF in the protocol validation group performed a maximal effort, and seven of them terminated the test within the 10±2 minute time frame. Backward linear regression analysis resulted in the following equation: W(peak) (W)=-142.865+2.998×Age (years)-19.206×Sex (0=male; 1=female)+1.328×Height (cm)+23.362×FEV(1) (L) (R=.89; R(2)=.79; SEE=21). Bland-Altman analysis showed no systematic bias between the actual and predicted W(peak).
CONCLUSION: We developed a CF-specific linear regression model to predict peak workload based on standard measures of anthropometry and FEV(1), which could be used to calculate individualized workload increments for a cycle ergometry testing protocol.
Copyright © 2012 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22704761     DOI: 10.1016/j.jcf.2012.05.004

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  8 in total

1.  Authors' Reply.

Authors:  Helge Hebestreit; Hubertus G M Arets; Paul Aurora; Steve Boas; Frank Cerny; Erik H J Hulzebos; Chantal Karila; Larry C Lands; John D Lowman; Anne Swisher; Don S Urquhart
Journal:  Respiration       Date:  2016-07-01       Impact factor: 3.580

2.  The relationship between cardiac hemodynamics and exercise tolerance in cystic fibrosis.

Authors:  Erik H Van Iterson; Courtney M Wheatley; Sarah E Baker; Wayne J Morgan; Eric M Snyder
Journal:  Heart Lung       Date:  2016-04-01       Impact factor: 2.210

3.  Exercise performance and quality of life in children with cystic fibrosis and mildly impaired lung function: relation with antibiotic treatments and hospitalization.

Authors:  Kristof Vandekerckhove; Michiel Keyzer; Jasper Cornette; Ilse Coomans; Filip Pyl; Frans De Baets; Petra Schelstraete; Filomeen Haerynck; Daniel De Wolf; Sabine Van Daele; Jan Boone
Journal:  Eur J Pediatr       Date:  2017-09-30       Impact factor: 3.183

4.  The Coupling of Peripheral Blood Pressure and Ventilatory Responses during Exercise in Young Adults with Cystic Fibrosis.

Authors:  Erik H Van Iterson; Courtney M Wheatley; Sarah E Baker; Thomas P Olson; Wayne J Morgan; Eric M Snyder
Journal:  PLoS One       Date:  2016-12-20       Impact factor: 3.240

5.  Cardiopulmonary responses to maximal aerobic exercise in patients with cystic fibrosis.

Authors:  Craig A Williams; Kyle C A Wedgwood; Hossein Mohammadi; Katie Prouse; Owen W Tomlinson; Krasimira Tsaneva-Atanasova
Journal:  PLoS One       Date:  2019-02-13       Impact factor: 3.752

6.  Variable agreement between wearable heart rate monitors during exercise in cystic fibrosis.

Authors:  Madeline Gaynor; Abbey Sawyer; Sue Jenkins; Jamie Wood
Journal:  ERJ Open Res       Date:  2019-10-30

7.  Sildenafil improves exercise capacity in patients with cystic fibrosis: a proof-of-concept clinical trial.

Authors:  Paula Rodriguez-Miguelez; Haruki Ishii; Nichole Seigler; Reva Crandall; Jeffrey Thomas; Caralee Forseen; Kathleen T McKie; Ryan A Harris
Journal:  Ther Adv Chronic Dis       Date:  2019-11-21       Impact factor: 5.091

8.  Exercise Stroke Volume in Adult Cystic Fibrosis: A Comparison of Acetylene Pulmonary Uptake and Oxygen Pulse.

Authors:  Erik H Van Iterson; Sarah E Baker; Courtney M Wheatley; Wayne J Morgan; Thomas P Olson; Eric M Snyder
Journal:  Clin Med Insights Circ Respir Pulm Med       Date:  2018-07-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.